(120) Anakinra has been observed to be efficacious in IEC-HS in patients treated with CD19 CAR T cell therapy for pediatric B-ALL, DLBCL, and mantle cell lymphoma. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.